1. Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 2016 with focus on leukaemias. Ann Oncol. 2016;27(4):725–731.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA: Cancer J Clin. 2017;67(1):7–30.
3. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921.
4. Asagi A, Ohta K, Nasu J, et al. Utility of contrast-enhanced FDG- PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence. Pancreas. 2013;42(1):11–19.
5. Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lan- cet (London, England). 2016;388(10041):248–257.
6. Hoshimoto S, Hishinuma S, Shirakawa H, et al. Prognostic sig- nificance of intraoperative peritoneal washing cytology for patients with potentially resectable pancreatic ductal adenocar- cinoma. Pancreatol. IAP. 2017;17(1):109–114.
7. Satoi S, Murakami Y, Motoi F, et al. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adeno- carcinoma who underwent margin-negative resection. J Gastrointest Surg. 2015;19(1):6–14 (discussion 14).
8. Simojoki M, Santala M, Vuopala S, Kauppila A. The prognostic value of peritoneal cytology in ovarian cancer. Eur J Gynaecol Oncol. 1999;20(5–6):357–360.
9. Ikoma N, Blum M, Chiang YJ, et al. Yield of staging laparoscopy and lavage cytology for radiologically occult peritoneal carci- nomatosis of gastric cancer. Ann Surg Oncol. 2016;23(13):4332–4337.
10. Chiu CC, Chen JJ, Su SB, Wang JJ. Value of peritoneal cytology in potentially resectable pancreatic cancer (Br J Surg 2013; 100: 1791–1796). Br J Surg. 2014;101(8):1031.
11. Yoshioka R, Saiura A, Koga R, et al. The implications of positive peritoneal lavage cytology in potentially resectable pancreatic cancer. World J Surg. 2012;36(9):2187–2191.
12. Yachida S, Fukushima N, Sakamoto M, Matsuno Y, Kosuge T, Hirohashi S. Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer. Br J Surg. 2002;89(5):573–578.
13. Aoyama T, Katayama Y, Murakawa M, et al. Clinical implication of peritoneal cytology in the pancreatic cancer patients who underwent curative resection followed by adjuvant gemcitabine or S-1 chemotherapy. Hepato-gastroenterology. 2015;62(137):200–206.
14. Cao F, Li J, Li A, Li F. Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: a systemic review and meta-analysis. Oncotarget. 2017;8(9):15004–15013.
15. Hirabayashi K, Imoto A, Yamada M, et al. Positive intraoperative peritoneal lavage cytology is a negative prognostic factor in pancreatic ductal adenocarcinoma: a retrospective single-center study. Front Oncol. 2015;5:182.
16. Iwagami Y, Eguchi H, Wada H, et al. Implications of peritoneal lavage cytology in resectable left-sided pancreatic cancer. Surg Today. 2015;45(4):444–450.
17. Sato K, Mori R, Hiroshima Y, et al. RT-PCR of peritoneal washings predicts peritoneal pancreatic cancer recurrence. J Surg Res. 2018;226:122–130.
18. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704–714.
19. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.
20. Song B, Zheng K, Ma H, et al. miR-429 determines poor outcome and inhibits pancreatic ductal adenocarcinoma growth by tar- geting TBK1. Cell Physiol Biochem. 2015;35(5):1846–1856.
21. Tokuhisa M, Ichikawa Y, Kosaka N, et al. Exosomal miRNAs from peritoneum lavage fluid as potential prognostic biomarkers of peritoneal metastasis in gastric cancer. PLoS One. 2015;10(7):e0130472.
22. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–196.
23. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–213.
24. Tsukamoto M, Iinuma H, Yagi T, Matsuda K, Hashiguchi Y. Circulating exosomal microRNA-21 as a biomarker in each tumor stage of colorectal cancer. Oncology. 2017;92(6):360–370.
25. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474.
26. Tempero MA, Arnoletti JP, Behrman S, et al. Pancreatic ade- nocarcinoma. J Natl Comp Cancer Netw. 2010;8(9):972–1017.
27. Ariake K, Motoi F, Ohtsuka H, et al. Predictive risk factors for peritoneal recurrence after pancreatic cancer resection and strategies for its prevention. Surg Today. 2017;47(12):1434–1442.
28. Zhang J, Zhao CY, Zhang SH, et al. Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma. Oncol Rep. 2014;31(3):1157–1164.
29. Mees ST, Mardin WA, Wendel C, et al. EP300–a miRNA-reg- ulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas. Int J Cancer. 2010;126(1):114–124.
30. Wei R, Ding C, Rodriguez RA, Del Mar Requena Mullor M. The SOX2OT/miR-194-5p axis regulates cell proliferation and mobility of gastric cancer through suppressing epithelial-mes- enchymal transition. Oncol Lett. 2018;16(5):6361–6368.
31. Jiang JH, Liu C, Cheng H, et al. Epithelial-mesenchymal tran- sition in pancreatic cancer: Is it a clinically significant factor? Biochim Biophys Acta. 2015;1855(1):43–49.
32. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–1428.
33. Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016;166(1):21–45.
34. Scheel C, Weinberg RA. Cancer stem cells and epithelial-mes- enchymal transition: concepts and molecular links. Sem Cancer Biol. 2012;22(5-6):396–403.
35. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131–142.
36. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gem- citabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–2406.
37. Roland CL, Yang AD, Katz MH, et al. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol. 2015;22(4):1168–1175.
38. Bradley A, Van Der Meer R. Upfront surgery versus neoadjuvant therapy for resectable pancreatic cancer: systematic review and Bayesian network meta-analysis. Sci Rep. 2019;9(1):4354.
39. Bradley A, Van Der Meer R. Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: a Markov decision analysis. PLoS One. 2019;14(2):e0212805.
40. Motoi F, Satoi S, Honda G, et al. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. J Gastroenterol. 2019;54(2):194–203.
41. Vietsch EE, van Eijck CH, Wellstein A. Circulating DNA and micro-RNA in patients with pancreatic cancer. Pancreatic Disorders Ther. 2015;5:2.
42. Meng J, Zhang D, Pan N, et al. Identification of miR-194-5p as a potential biomarker for postmenopausal osteoporosis. PeerJ. 2015;3:e971.
43. van der Ree MH, Jansen L, Kruize Z, et al. Plasma microRNA levels are associated with hepatitis B e antigen status and treat- ment response in chronic hepatitis B patients. J Infect Dis. 2017;215(9):1421–1429.